Abiraterone
The serum concentration of Methylphenidate can be increased when it is combined with Abiraterone.
Acebutolol
Methylphenidate may decrease the antihypertensive activities of Acebutolol.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Methylphenidate.
Advertisement
Acepromazine
The risk or severity of adverse effects can be increased when Acepromazine is combined with Methylphenidate.
Aceprometazine
The risk or severity of adverse effects can be increased when Aceprometazine is combined with Methylphenidate.
Acetophenazine
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Methylphenidate.
Advertisement
Aliskiren
Methylphenidate may decrease the antihypertensive activities of Aliskiren.
Alprenolol
Methylphenidate may decrease the antihypertensive activities of Alprenolol.
Aluminum
Aluminium can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Advertisement
Aluminum Hydroxide
Aluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
aluminum hydroxide, dried (USP)
Aluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Aluminum Magnesium Silicate
Almasilate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Amantadine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amantadine.
Ambrisentan
Methylphenidate may decrease the antihypertensive activities of Ambrisentan.
Amineptin
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amineptine.
Amiodarone
The metabolism of Methylphenidate can be decreased when combined with Amiodarone.
Amisulpride
The risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate.
Amitriptyline
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amitriptyline.
Amlodipine
Methylphenidate may decrease the antihypertensive activities of Amlodipine.
Amoxapine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amoxapine.
Amphetamine
Amphetamine may increase the hypertensive activities of Methylphenidate.
Apomorphine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Apomorphine.
Aripiprazole
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.
Artemether
The metabolism of Methylphenidate can be decreased when combined with Artemether.
Asenapine
The risk or severity of adverse effects can be increased when Asenapine is combined with Methylphenidate.
Atenolol
Methylphenidate may decrease the antihypertensive activities of Atenolol.
Atomoxetine
The metabolism of Methylphenidate can be decreased when combined with Atomoxetine.
Benazepril
Methylphenidate may decrease the antihypertensive activities of Benazepril.
Bendroflumethiazide
Methylphenidate may decrease the antihypertensive activities of Bendroflumethiazide.
Benperidol
The risk or severity of adverse effects can be increased when Benperidol is combined with Methylphenidate.
Bepridil
Methylphenidate may decrease the antihypertensive activities of Bepridil.
Betaxolol
Methylphenidate may decrease the antihypertensive activities of Betaxolol.
Bethanidine
Methylphenidate may decrease the antihypertensive activities of Bethanidine.
Bimatoprost
Methylphenidate may decrease the antihypertensive activities of Bimatoprost.
Bismuth Subcitrate
Bismuth Subcitrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Bisoprolol
Methylphenidate may decrease the antihypertensive activities of Bisoprolol.
Bosentan
Methylphenidate may decrease the antihypertensive activities of Bosentan.
Bretylium
Methylphenidate may decrease the antihypertensive activities of Bretylium.
Brexpiprazole
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methylphenidate.
Brimonidine
Methylphenidate may decrease the antihypertensive activities of Brimonidine.
Bromocriptine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.
Bromperidol
The risk or severity of adverse effects can be increased when Bromperidol is combined with Methylphenidate.
Bupranolol
Methylphenidate may decrease the antihypertensive activities of Bupranolol.
Bupropion
The metabolism of Methylphenidate can be decreased when combined with Bupropion.
Cafedrine
Methylphenidate may decrease the antihypertensive activities of Cafedrine.
Calcium Carbonate
Calcium Carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
CALCIUM CARBONATE, PRECIPITATED
Calcium Carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Candesartan
Methylphenidate may decrease the antihypertensive activities of Candesartan.
Candesartan Cilexetil
Methylphenidate may decrease the antihypertensive activities of Candesartan cilexetil.
Captopril
Methylphenidate may decrease the antihypertensive activities of Captopril.
Cariprazine
The risk or severity of adverse effects can be increased when Cariprazine is combined with Methylphenidate.
Carteolol
Methylphenidate may decrease the antihypertensive activities of Carteolol.
Carvedilol
Methylphenidate may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The metabolism of Methylphenidate can be decreased when combined with Celecoxib.
Celiprolol
Methylphenidate may decrease the antihypertensive activities of Celiprolol.
Chloroquine
The metabolism of Methylphenidate can be decreased when combined with Chloroquine.
Chlorothiazide
Methylphenidate may decrease the antihypertensive activities of Chlorothiazide.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylphenidate.
Chlorprothixene
The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate.
Chlorthalidone
Methylphenidate may decrease the antihypertensive activities of Chlorthalidone.
Cholecalciferol
The metabolism of Methylphenidate can be decreased when combined with Cholecalciferol.
Cicletanine
Methylphenidate may decrease the antihypertensive activities of Cicletanine.
Cilazapril
Methylphenidate may decrease the antihypertensive activities of Cilazapril.
Cimetidine
Cimetidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Cinacalcet
The metabolism of Methylphenidate can be decreased when combined with Cinacalcet.
Citalopram
The metabolism of Methylphenidate can be decreased when combined with Citalopram.
Clemastine
The metabolism of Methylphenidate can be decreased when combined with Clemastine.
Clobazam
The metabolism of Methylphenidate can be decreased when combined with Clobazam.
Clofezone
Rabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Clomipramine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Clomipramine.
Clonidine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine.
Clotrimazole
The metabolism of Methylphenidate can be decreased when combined with Clotrimazole.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Methylphenidate.
Cobicistat
The serum concentration of Methylphenidate can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Methylphenidate can be decreased when combined with Cocaine.
Cryptenamine
Methylphenidate may decrease the antihypertensive activities of Cryptenamine.
Cyamemazine
The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Cyclobenzaprine.
Cyclopenthiazide
Methylphenidate may decrease the antihypertensive activities of Cyclopenthiazide.
Cyclothiazide
Methylphenidate may decrease the antihypertensive activities of Cyclothiazide.
Dapiprazole
The risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylphenidate.
Darifenacin
The metabolism of Methylphenidate can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Methylphenidate can be increased when it is combined with Darunavir.
Debrisoquin
Methylphenidate may decrease the antihypertensive activities of Debrisoquin.
Delavirdine
The metabolism of Methylphenidate can be decreased when combined with Delavirdine.
Deserpidine
Methylphenidate may decrease the antihypertensive activities of Deserpidine.
Desflurane
Methylphenidate may increase the hypertensive activities of Desflurane.
Desipramine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine.
Dexlansoprazole
Dexlansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Diazoxide
Methylphenidate may decrease the antihypertensive activities of Diazoxide.
Dicumarol
The serum concentration of Dicoumarol can be increased when it is combined with Methylphenidate.
Dihydralazine
Methylphenidate may decrease the antihypertensive activities of Dihydralazine.
Diltiazem
Methylphenidate may decrease the antihypertensive activities of Diltiazem.
Diphenhydramine
The metabolism of Methylphenidate can be decreased when combined with Diphenhydramine.
Dorzolamide
Methylphenidate may decrease the antihypertensive activities of Dorzolamide.
Dothiepin
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Dosulepin.
Doxazosin
Methylphenidate may decrease the antihypertensive activities of Doxazosin.
Doxepin
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Doxepin.
Dronedarone
The metabolism of Methylphenidate can be decreased when combined with Dronedarone.
Droperidol
The risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate.
Duloxetine
The metabolism of Methylphenidate can be decreased when combined with Duloxetine.
Eliglustat
The metabolism of Methylphenidate can be decreased when combined with Eliglustat.
Enalapril
Methylphenidate may decrease the antihypertensive activities of Enalapril.
Enalaprilat
Methylphenidate may decrease the antihypertensive activities of Enalaprilat.
Enalaprilat Anhydrous
Methylphenidate may decrease the antihypertensive activities of Enalaprilat.
Enflurane
Methylphenidate may increase the hypertensive activities of Enflurane.
Epinastine
Epinastine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Epoprostenol
Methylphenidate may decrease the antihypertensive activities of Epoprostenol.
Eprosartan
Methylphenidate may decrease the antihypertensive activities of Eprosartan.
Esomeprazole
Esomeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Ethanol
The risk or severity of adverse effects can be increased when Ethanol is combined with Methylphenidate.
Famotidine
Famotidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Felodipine
Methylphenidate may decrease the antihypertensive activities of Felodipine.
Fenoldopam
Methylphenidate may decrease the antihypertensive activities of Fenoldopam.
Ferulic Acid
Methylphenidate may decrease the antihypertensive activities of Ferulic acid.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methylphenidate.
Fluindione
The serum concentration of Fluindione can be increased when it is combined with Methylphenidate.
Fluoxetine
The metabolism of Methylphenidate can be decreased when combined with Fluoxetine.
Flupenthixol
The risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.
Fluspirilene
The risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate.
Fluvoxamine
The metabolism of Methylphenidate can be decreased when combined with Fluvoxamine.
Fosinopril
Methylphenidate may decrease the antihypertensive activities of Fosinopril.
Fosphenytoin
The serum concentration of Fosphenytoin can be increased when it is combined with Methylphenidate.
Furazolidone
Furazolidone may increase the hypertensive activities of Methylphenidate.
Guanabenz
Methylphenidate may decrease the antihypertensive activities of Guanabenz.
Guanadrel
Methylphenidate may decrease the antihypertensive activities of Guanadrel.
Guanethidine
Methylphenidate may decrease the antihypertensive activities of Guanethidine.
Guanfacine
Methylphenidate may decrease the antihypertensive activities of Guanfacine.
Haloperidol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.
Halothane
Methylphenidate may increase the hypertensive activities of Halothane.
Hydralazine
Methylphenidate may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
Methylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide.
Hydroflumethiazide
Methylphenidate may decrease the antihypertensive activities of Hydroflumethiazide.
Hydrotalcite
Hydrotalcite can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Iloperidone
The risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate.
Imidapril
Methylphenidate may decrease the antihypertensive activities of Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.
Indapamide
Methylphenidate may decrease the antihypertensive activities of Indapamide.
Indinavir
The metabolism of Methylphenidate can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Methylphenidate can be decreased when combined with Indinavir.
Indoramin
Methylphenidate may decrease the antihypertensive activities of Indoramin.
Ioflupane I-123
Methylphenidate may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.
Iproniazid
Iproniazid may increase the hypertensive activities of Methylphenidate.
Irbesartan
Methylphenidate may decrease the antihypertensive activities of Irbesartan.
Isocarboxazid
Isocarboxazid may increase the hypertensive activities of Methylphenidate.
Isoflurane
Methylphenidate may increase the hypertensive activities of Isoflurane.
Isoniazid
The metabolism of Methylphenidate can be decreased when combined with Isoniazid.
Isradipine
Methylphenidate may decrease the antihypertensive activities of Isradipine.
Ketanserin
Methylphenidate may decrease the antihypertensive activities of Ketanserin.
Ketoconazole
The metabolism of Methylphenidate can be decreased when combined with Ketoconazole.
Labetalol
Methylphenidate may decrease the antihypertensive activities of Labetalol.
Lacidipine
Methylphenidate may decrease the antihypertensive activities of Lacidipine.
Lansoprazole
Lansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Latanoprost
Methylphenidate may decrease the antihypertensive activities of Latanoprost.
Lercanidipine
Methylphenidate may decrease the antihypertensive activities of Lercanidipine.
Levodopa
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Levodopa.
Lisinopril
Methylphenidate may decrease the antihypertensive activities of Lisinopril.
Lisinopril Anhydrous
Methylphenidate may decrease the antihypertensive activities of Lisinopril.
Lithium
The risk or severity of adverse effects can be increased when Lithium is combined with Methylphenidate.
Lithium Cation
The risk or severity of adverse effects can be increased when Lithium is combined with Methylphenidate.
Lofexidine
Methylphenidate may decrease the antihypertensive activities of Lofexidine.
Lopinavir
The metabolism of Methylphenidate can be decreased when combined with Lopinavir.
Lorcaserin
The metabolism of Methylphenidate can be decreased when combined with Lorcaserin.
Losartan
Methylphenidate may decrease the antihypertensive activities of Losartan.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate.
Lumefantrine
The metabolism of Methylphenidate can be decreased when combined with Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.
Macitentan
Methylphenidate may decrease the antihypertensive activities of Macitentan.
Magaldrate
Magaldrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Magnesium Hydroxide
Magnesium hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Magnesium Oxide
Magnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Magnesium Trisilicate
Magnesium Trisilicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Manidipine
Methylphenidate may decrease the antihypertensive activities of Manidipine.
Mecamylamine
Methylphenidate may decrease the antihypertensive activities of Mecamylamine.
Mesoridazine
The risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylphenidate.
Methadone
The metabolism of Methylphenidate can be decreased when combined with Methadone.
Methantheline
Methantheline can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Methotrimeprazine
The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate.
Methoxyflurane
Methylphenidate may increase the hypertensive activities of Methoxyflurane.
Methyldopa
Methylphenidate may decrease the antihypertensive activities of Methyldopa.
METHYLDOPA ANHYDROUS
Methylphenidate may decrease the antihypertensive activities of Methyldopa.
Methylene blue
Methylene blue may increase the hypertensive activities of Methylphenidate.
Metipranolol
Methylphenidate may decrease the antihypertensive activities of Metipranolol.
Metolazone
Methylphenidate may decrease the antihypertensive activities of Metolazone.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Methylphenidate.
Metylperon
The risk or severity of adverse effects can be increased when Melperone is combined with Methylphenidate.
Metyrosine
Methylphenidate may decrease the antihypertensive activities of Metyrosine.
Mibefradil
Methylphenidate may decrease the antihypertensive activities of Mibefradil.
Midostaurin
The metabolism of Methylphenidate can be decreased when combined with Midostaurin.
Minaprine
Minaprine may increase the hypertensive activities of Methylphenidate.
Minoxidil
Methylphenidate may decrease the antihypertensive activities of Minoxidil.
Mirabegron
The metabolism of Methylphenidate can be decreased when combined with Mirabegron.
Mirtazapine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Mirtazapine.
Moclobemide
Moclobemide may increase the hypertensive activities of Methylphenidate.
Moexipril
Methylphenidate may decrease the antihypertensive activities of Moexipril.
Molindone
The risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate.
Moxonidine
Methylphenidate may decrease the antihypertensive activities of Moxonidine.
Nadolol
Methylphenidate may decrease the antihypertensive activities of Nadolol.
Nebivolol
Methylphenidate may decrease the antihypertensive activities of Nebivolol.
Nevirapine
The metabolism of Methylphenidate can be decreased when combined with Nevirapine.
Nialamide
Nialamide may increase the hypertensive activities of Methylphenidate.
Nicardipine
Methylphenidate may decrease the antihypertensive activities of Nicardipine.
Nicorandil
Methylphenidate may decrease the antihypertensive activities of Nicorandil.
Nilotinib
The metabolism of Methylphenidate can be decreased when combined with Nilotinib.
Nilvadipine
Methylphenidate may decrease the antihypertensive activities of Nilvadipine.
Nimodipine
Methylphenidate may decrease the antihypertensive activities of Nimodipine.
Nisoldipine
Methylphenidate may decrease the antihypertensive activities of Nisoldipine.
Nitrendipine
Methylphenidate may decrease the antihypertensive activities of Nitrendipine.
Nitroprusside
Methylphenidate may decrease the antihypertensive activities of Nitroprusside.
Nitrous Oxide
Methylphenidate may increase the hypertensive activities of Nitrous oxide.
Nizatidine
Nizatidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Nortriptyline
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Nortriptyline.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenidate.
Olmesartan
Methylphenidate may decrease the antihypertensive activities of Olmesartan.
Omeprazole
Omeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Ondansetron
The risk or severity of adverse effects can be increased when Ondansetron is combined with Methylphenidate.
Opipramol
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Opipramol.
Oxprenolol
Methylphenidate may decrease the antihypertensive activities of Oxprenolol.
Paliperidone
The risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate.
Panobinostat
The serum concentration of Methylphenidate can be increased when it is combined with Panobinostat.
Pantoprazole
Pantoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Pargyline
Methylphenidate may decrease the antihypertensive activities of Pargyline.
Paroxetine
The metabolism of Methylphenidate can be decreased when combined with Paroxetine.
Peginterferon Alfa-2b
The serum concentration of Methylphenidate can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
Methylphenidate may decrease the antihypertensive activities of Penbutolol.
Perazine
The risk or severity of adverse effects can be increased when Perazine is combined with Methylphenidate.
Periciazine
The risk or severity of adverse effects can be increased when Propericiazine is combined with Methylphenidate.
Perindopril
Methylphenidate may decrease the antihypertensive activities of Perindopril.
Perphenazine
The risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.
Phenelzine
Phenelzine may increase the hypertensive activities of Methylphenidate.
Phenindione
The serum concentration of Phenindione can be increased when it is combined with Methylphenidate.
Phenobarbital
The serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate.
Phenoxybenzamine
Methylphenidate may decrease the antihypertensive activities of Phenoxybenzamine.
Phenprocoumon
The serum concentration of Phenprocoumon can be increased when it is combined with Methylphenidate.
Phentolamine
Methylphenidate may decrease the antihypertensive activities of Phentolamine.
Phentolamine Mesylate
Methylphenidate may decrease the antihypertensive activities of Phentolamine.
Phenytoin
The serum concentration of Phenytoin can be increased when it is combined with Methylphenidate.
Pimozide
The risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate.
Pinacidil
Methylphenidate may decrease the antihypertensive activities of Pinacidil.
Pindolol
Methylphenidate may decrease the antihypertensive activities of Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Methylphenidate.
Pipothiazine
The risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenidate.
Piribedil
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Piribedil.
Polythiazide
Methylphenidate may decrease the antihypertensive activities of Polythiazide.
Pramipexole
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole.
Prazosin
Methylphenidate may decrease the antihypertensive activities of Prazosin.
Primidone
The serum concentration of the active metabolites of Primidone can be increased when Primidone is used in combination with Methylphenidate.
Procarbazine
Procarbazine may increase the hypertensive activities of Methylphenidate.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.
Promazine
The risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate.
Promethazine
Promethazine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Propranolol
Methylphenidate may decrease the antihypertensive activities of Propranolol.
Prothipendyl
The risk or severity of adverse effects can be increased when Prothipendyl is combined with Methylphenidate.
Protriptyline
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.
Quinapril
Methylphenidate may decrease the antihypertensive activities of Quinapril.
Quinidine
The metabolism of Methylphenidate can be decreased when combined with Quinidine.
Quinine
The metabolism of Methylphenidate can be decreased when combined with Quinine.
Rabeprazole
Rabeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Ramipril
Methylphenidate may decrease the antihypertensive activities of Ramipril.
Ranitidine
Ranitidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Ranolazine
The metabolism of Methylphenidate can be decreased when combined with Ranolazine.
Rasagiline
Rasagiline may increase the hypertensive activities of Methylphenidate.
Remoxipride
The risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate.
Rescinnamine
Methylphenidate may decrease the antihypertensive activities of Rescinnamine.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Methylphenidate.
Rilmenidine
Methylphenidate may decrease the antihypertensive activities of Rilmenidine.
Riociguat
Methylphenidate may decrease the antihypertensive activities of Riociguat.
Risperidone
The risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.
Ritonavir
The metabolism of Methylphenidate can be decreased when combined with Ritonavir.
Rolapitant
The metabolism of Methylphenidate can be decreased when combined with Rolapitant.
Ropinirole
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Ropinirole.
Rotigotine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Rotigotine.
Roxatidine Acetate
Roxatidine acetate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Rucaparib
The metabolism of Methylphenidate can be decreased when combined with Rucaparib.
Selegiline
Selegiline may increase the hypertensive activities of Methylphenidate.
Selexipag
Methylphenidate may decrease the antihypertensive activities of Selexipag.
Sertindole
The risk or severity of adverse effects can be increased when Sertindole is combined with Methylphenidate.
Sertraline
The metabolism of Methylphenidate can be decreased when combined with Sertraline.
Sevoflurane
Methylphenidate may increase the hypertensive activities of Sevoflurane.
Sodium Bicarbonate
Sodium bicarbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Spirapril
Methylphenidate may decrease the antihypertensive activities of Spirapril.
Sulpiride
The risk or severity of adverse effects can be increased when Sulpiride is combined with Methylphenidate.
Talinolol
Methylphenidate may decrease the antihypertensive activities of Talinolol.
Telmisartan
Methylphenidate may decrease the antihypertensive activities of Telmisartan.
Terbinafine
The metabolism of Methylphenidate can be decreased when combined with Terbinafine.
Terlipressin
Methylphenidate may decrease the antihypertensive activities of Terlipressin.
Theodrenaline
Methylphenidate may decrease the antihypertensive activities of Theodrenaline.
Thioproperazine
The risk or severity of adverse effects can be increased when Thioproperazine is combined with Methylphenidate.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Methylphenidate.
Thiothixene
The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.
Tianeptine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Tianeptine.
Tiapride
The risk or severity of adverse effects can be increased when Tiapride is combined with Methylphenidate.
Tibolone
Methylphenidate may decrease the antihypertensive activities of Tibolone.
Ticlopidine
The metabolism of Methylphenidate can be decreased when combined with Ticlopidine.
Timolol
Methylphenidate may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Methylphenidate may decrease the antihypertensive activities of Timolol.
Tipranavir
The metabolism of Methylphenidate can be decreased when combined with Tipranavir.
Tolazoline
Methylphenidate may decrease the antihypertensive activities of Tolazoline.
Toloxatone
Toloxatone may increase the hypertensive activities of Methylphenidate.
Torsemide
Methylphenidate may decrease the antihypertensive activities of Torasemide.
Trandolapril
Methylphenidate may decrease the antihypertensive activities of Trandolapril.
Tranylcypromine
The metabolism of Methylphenidate can be decreased when combined with Tranylcypromine.
Travoprost
Methylphenidate may decrease the antihypertensive activities of Travoprost.
Treprostinil
Methylphenidate may decrease the antihypertensive activities of Treprostinil.
Trichlormethiazide
Methylphenidate may decrease the antihypertensive activities of Trichlormethiazide.
Trifluoperazine
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.
Triflupromazine
The risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate.
Trimethaphan
Methylphenidate may decrease the antihypertensive activities of Trimethaphan.
Trimipramine
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.
Tromethamine
Tromethamine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
UNOPROSTONE
Methylphenidate may decrease the antihypertensive activities of Unoprostone.
Urapidil
Methylphenidate may decrease the antihypertensive activities of Urapidil.
Valsartan
Methylphenidate may decrease the antihypertensive activities of Valsartan.
Venlafaxine
The metabolism of Methylphenidate can be decreased when combined with Venlafaxine.
Vincamine
Methylphenidate may decrease the antihypertensive activities of Vincamine.
Vinpocetine
Methylphenidate may decrease the antihypertensive activities of Vinpocetine.
Warfarin
The serum concentration of Warfarin can be increased when it is combined with Methylphenidate.
Xylometazoline
Methylphenidate may decrease the antihypertensive activities of Xylometazoline.
Ziprasidone
The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate.
Zofenopril
Methylphenidate may decrease the antihypertensive activities of Zofenopril.
Zotepine
The risk or severity of adverse effects can be increased when Zotepine is combined with Methylphenidate.
Zuclopenthixol
The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.
